Streetbeat News

Products Services

LFWD

ReWalk Robotics Ltd. (DBA Lifeward), announced that CMS has deferred its final decision on the payment rate for personal exoskeletons, affecting the pricing determination for ReWalk Personal Exoskeletons. The decision, part of CMS' HCPCS coding memorandum, means payments will continue on a case-by-case basis. Lifeward has delivered 35 Personal Exoskeletons to Medicare beneficiaries and remains committed to supporting pricing considerations for its stair-enabled ReWalk Exoskeleton.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:48 pm

XPEV

XPeng Inc. (NYSE:XPEV) shares are up in premarket trading after the company reported a decrease in Smart EV deliveries year over year but showed strong performance in the electric MPV and three-row seater BEV segments with its X9 model. Additionally, XPENG announced the rollout of its unlimited XNGP ADAS function for experienced users in China, leading to a significant increase in smart driving mileage among its car owners during the Chinese New Year holiday.

Portfolio Pulse from Nabaparna Bhattacharya

March 01, 2024 | 1:48 pm

NTIP

Network-1 Technologies, Inc. has been granted a new patent by the U.S. Patent Office, expanding its Machine-to-Machine (M2M)/Internet of Things (IoT) patent portfolio to a total of 51 patents worldwide. This development strengthens the company's intellectual property position in the rapidly growing M2M/IoT sector.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:47 pm

VEEV

Veeva Systems Inc (NYSE:VEEV) shares dropped premarket after reporting Q4 FY24 results. Despite beating revenue and EPS estimates, with a 12% Y/Y revenue increase to $630.6 million and adjusted EPS of $1.38, the company's Q1 and FY25 revenue outlooks were slightly below consensus expectations. The company highlighted its long-term growth initiatives, including the Veeva Compass Suite, Clinical Platform, and new Commercial Cloud.

Portfolio Pulse from Lekha Gupta

March 01, 2024 | 1:45 pm

HOOD

SOLUSD

Robinhood (NASDAQ:HOOD) has added Dogwifhat (CRYPTO: WIF) to its trading platform, resulting in a 28% increase in WIF's value and reaching a $1B market cap. The listing on Robinhood Europe and the potential for future listings on other major exchanges like Coinbase highlight the growing acceptance of meme coins in the cryptocurrency market. WIF, launched on Solana (CRYPTO: SOL) in December 2023, has seen substantial growth, with expectations of continued interest from retail traders.

Portfolio Pulse from Murtuza Merchant

March 01, 2024 | 1:39 pm

BIVI

FSR

NYCB

Fisker (FSR) shares plummeted by 41% due to disappointing Q4 results and doubts about its ongoing viability. New York Community Bancorp (NYCB) fell 31% after revealing material weaknesses in its internal controls. Conversely, BioVie (BIVI) surged 236% on promising data for its NE3107 treatment for Parkinson's and Alzheimer's, to be presented at a 2024 conference.

Portfolio Pulse from ryanfaloona@benzinga.com

March 01, 2024 | 1:36 pm

SCOR

TGNA

Comscore, Inc. (NASDAQ:SCOR) and TEGNA Inc. (NYSE:TGNA) have entered into a multi-year agreement for local linear and cross-platform audience measurement. Comscore will continue as a key measurement partner across all TEGNA markets, providing metrics for local TV, major affiliate, and digital businesses. This partnership aims to deliver value for TEGNA's advertisers across linear and digital platforms by leveraging Comscore's local market data and cross-platform capabilities. Financial details of the agreement were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:35 pm

NRXP

NRx Pharmaceuticals has entered into a definitive purchase agreement with an existing investor for the sale of 2.7 million shares at $0.38 per share, raising approximately $1.0 million. This represents a 26.7% premium over the recent share offering. The deal also includes a 5-year warrant with a $0.40 per share strike price. The funds will support the company's development pipeline, including projects on Suicidal Depression, Suicidal Bipolar Depression, and Chronic Pain, in addition to general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:33 pm

EOLS

Evolus, Inc. (NASDAQ:EOLS) announced its dermal filler product (Evolysse™/Estyme® Lift) showed statistical superiority over Restylane-L in a European study, meeting its primary endpoint of non-inferiority at 3 and 6 months. The company plans to launch the first-generation Cold HA Technology globally in 2025, with FDA filing expected in summer 2024. The study, which enrolled 45 patients, demonstrated the safety and effectiveness of the Evolysse™/Estyme® Lift filler. Additionally, Evolus has entered into exclusive distribution agreements with Symatese for the US and Europe, expanding its market by 78% to approximately $6 billion.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:32 pm

SLS

SELLAS Life Sciences announced successful Phase 1 results for SLS009 in treating acute myeloid leukemia (AML) at the 2024 European School of Haematology Conference. The study met all objectives, including pharmacokinetic, pharmacodynamic, safety, and clinical activity. A notable achievement was a complete remission (CR) in a patient after three months, lasting eight months, with one-year survival at the latest assessment. This marks the first instance of CR with CDK9 inhibition monotherapy in a relapsed/refractory AML patient. Phase 2a data is expected in March and Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:31 pm